Akero Therapeutics — Corporate Update (March 2020)
10 slides from Akero Therapeutics's corporate update, Mar 31, 2020
Slide 1: A Global Disease, A Pioneering Treatment: AKR-001 Phase 2a BALANCED Study Week 12 Efficacy Endpoints
A Global Disease, A Pioneering Treatment AKR - 001 Phase 2a BALANCED Study Week 12 Efficacy Endpoints Akero Therapeutics, Inc. March 31, 2020
Slide 2: Safe Harbor
- CONFIDENTIAL - 2 SAFE HARBOR This presentation has been prepared by Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) and is made for in formational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any s
Slide 3: AKR-001 Met All Week 12 Efficacy Endpoints
- CONFIDENTIAL - Efficacy Measures Blinded Safety & Tolerability AKR - 001 MET ALL WEEK 12 EFFICACY ENDPOINTS 3 • All AKR - 001 dose groups met the primary endpoint, with statistically significant absolute reductions in liver fat of 12 - 14% • Statistically significant relative reductions in liver f
Slide 4: The BALANCED Study Trial Design
- CONFIDENTIAL - 4 THE BALANCED STUDY TRIAL DESIGN MRI - PDFF Liver Biopsy 12 Weeks Screening Randomization AKR - 001 70 mg (n=20) QW SC Injection AKR - 001 50 mg (n=20) QW SC Injection AKR - 001 28 mg (n=20) QW SC Injection Placebo (n=20) QW SC Injection Liver Biopsy Safety FU – Week 20 Week 6 Scre
Slide 5: Baseline Demographics
- CONFIDENTIAL - 5 BASELINE DEMOGRAPHICS Parameter Mean Placebo (N=21) AKR - 001 28mg (N=19) AKR - 001 50mg (N=20) AKR - 001 70mg (N=20) Age (Years) 52 50 53 53 Sex (Male/Female) 6/15 9/10 10/10 9/11 Weight (kg) 99.6 108.2 103.5 103.1 BMI (kg/m 2 ) 37.6 38.8 36.7 37.2 Liver Fat Content (% by MRI - P
Slide 6: Absolute Reduction in Liver Fat: Dose Groups Met Primary Endpoint
- CONFIDENTIAL - ABSOLUTE REDUCTION IN LIVER FAT: All AKR - 001 Dose Groups Met Primary Endpoint Absolute Reduction in Liver Fat (%) - 0.3 - 12.3 *** - 13.4 *** - 14.1 *** -15 -10 -5 0 Placebo AKR-001 28 mg QW AKR-001 50 mg QW AKR-001 70 mg QW 6 Mean Change From Baseline to Week 12 Normalization of
Slide 7: Relative Reduction in Liver Fat: Dose Groups Met Secondary Endpoint
- CONFIDENTIAL - RELATIVE REDUCTION IN LIVER FAT: All AKR - 001 Dose Groups Met Secondary Endpoint Relative Reduction in Liver Fat 0% - 63% *** - 71% *** - 72% *** -80% -70% -60% -50% -40% -30% -20% -10% 0% Placebo AKR-001 28 mg QW AKR-001 50 mg QW AKR-001 70 mg QW 7 Mean Change From Baseline to Wee
Slide 8: Reduction in ALT: Dose Groups Met Secondary Endpoint
- CONFIDENTIAL - REDUCTION IN ALT: All AKR - 001 Dose Groups Met Secondary Endpoint Reduction in ALT (U/L) - 6 - 24 *** - 30 *** - 32 *** -40 -35 -30 -25 -20 -15 -10 -5 0 Placebo AKR-001 28 mg QW AKR-001 50 mg QW AKR-001 70 mg QW 8 Mean Change From Baseline to Week 12 *** p<0.001, versus placebo An
Slide 9: AKR-001: Potential as a Cornerstone NASH Therapy
- CONFIDENTIAL - AKR - 001 POTENTIAL AS A CORNERSTONE NASH THERAPY 9 x All AKR - 001 dose groups met the primary endpoint for absolute reduction in liver fat x All AKR - 001 dose groups met secondary endpoints for relative reduction in liver fat and ALT reduction x Readout of biopsy data is expected
Slide 10: A Global Disease, A Pioneering Treatment
A Global Disease, A Pioneering Treatment NASDAQ: AKRO